stockrowTG Therapeutics, Inc.
TGTX Healthcare Biotechnology
TG Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $616.3 million, up 87.3% from fiscal 2024.
- Revenue
- +70.3%
- EPS
- −73.7%
- Free cash flow
- +427.1%
- Total debt
- +204.2%
Quarter to June 2026, against a year earlier
Follow TGTX
Alert me
TG Therapeutics, Inc. (TGTX) Book value per share
TG Therapeutics, Inc.'s book value per share at the end of fiscal 2025 was 4.5×, up 193.4% from 1.5× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 4.3×. Over the past ten years it has ranged from 0.3× (fiscal 2018) to 4.5× (fiscal 2020); the current reading is higher than 91% of that period. TG Therapeutics, Inc. ranks 168th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 4.5× | 193.45% |
| FY2024 | 1.5× | 35.33% |
| FY2023 | 1.1× | 161.31% |
| FY2022 | 0.4× | (75.88%) |
| FY2021 | 1.8× | (60.17%) |
| FY2020 | 4.5× | 930.43% |
| FY2019 | 0.4× | 37.21% |
| FY2018 | 0.3× | (70.49%) |
| FY2017 | 1.1× | 47.57% |
| FY2016 | 0.7× | (67.13%) |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 4.3× | 5.54% |
| Mar 2026 | 4.0× | (10.09%) |
| Dec 2025 | 4.5× | 7.53% |
| Sep 2025 | 4.2× | 121.66% |
| 42 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| KRYS Krystal Biotech, Inc. compare | 48.5× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 21.4× |
| PTGX Protagonist Therapeutics, Inc. compare | 12.8× |
| SYRE Spyre Therapeutics, Inc. compare | 11.9× |
| TWST Twist Bioscience Corporation compare | 7.1× |
| TGTX TG Therapeutics, Inc. | 4.3× |
| CYTK Cytokinetics, Incorporated compare | 0.0× |
| CAI Caris Life Sciences,�Inc. compare | 0.0× |
| IBRX ImmunityBio, Inc. compare | −1.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on TGTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement